✉ Email this page to a colleague
« Back to Dashboard
Mapracorat is an investigational drug.
There have been 12 clinical trials for Mapracorat. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2012.
The most common disease conditions in clinical trials are Inflammation, Cataract, and Dermatitis, Atopic. The leading clinical trial sponsors are Bausch & Lomb Incorporated, Bayer, and [disabled in preview].
Recent Clinical Trials for Mapracorat
|1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat||Bayer||Phase 1|
|Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days||Bausch & Lomb Incorporated||Phase 1|
|Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery||Bausch & Lomb Incorporated||Phase 3|